natgillin/translations-raw huggingface dataset:
Administration of the strong CYP3A4 inducer rifampicin (600 mg daily for 31 days) to healthy volunteers increased cabozantinib clearance (4.3-fold) and decreased single-dose plasma cabozantinib exposure (AUC) by 77%.
Primjena jakog induktora CYP3A4 rifampicina (600 mg dnevno tijekom 31 dana) u zdravih dobrovoljaca izazvala je povećanje klirensa kabozantiniba (za 4,3 puta) te smanjenje plazmatske izloženosti kabozantinibu (AUC) za 77 %.
Administration of the veterinary medicinal product by the subcutaneous route in cattle and the intramuscular route in pigs is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in cattle treated in clinical studies
Veterinarsko-medicinski proizvod primijenjen subkutanim putem u goveda i intramuskularnim putem u svinja dobro se podnosi; u goveda liječenih u kliničkim studijama uočeno je samo blago prolazno oticanje na mjestu ubrizgavanja, nakon subkutane primjene.
Administration of the ZALTRAP/FOLFIRI should be delayed until platelet count is 75 x 109/L (see section 4.2).
Primjenu protokola ZALTRAP/FOLFIRI treba odgoditi dok broj trombocita ne bude 75 x 109/l (vidjeti dio 4.2).
Administration of TMZ with food resulted in a 33 % decrease in Cmax and a 9 % decrease in area under the curve (AUC).
Primjena TMZ-a s hranom dovela je do smanjenja Cmax za 33%, a površine ispod krivulje (AUC) za 9%.
Administration of TMZ with food resulted in a 33% decrease in Cmax and a 9% decrease in area under the curve (AUC).
Primjena TMZ-a s hranom dovela je do smanjenja Cmax za 33%, a površine ispod krivulje (AUC) za 9%.
Administration of tolvaptan may cause too rapid increases in serum sodium (≥ 12 mmol/l per 24 hours, please see below); therefore, monitoring of serum sodium in all patients should start no later than 4-6 hours after treatment initiation.
Primjena tolvaptana može dovesti do prebrzog povećanja serumskog natrija (≥ 12 mmol/l u 24 sata, molimo pogledajte ispod), stoga, sve bolesnike treba početi nadzirati radi serumskog natrija ne kasnije od 4 – 6 sati nakon početka liječenja.
Administration of trastuzumab emtansine was well tolerated in rats and monkeys at doses up to 20 and 10 mg/kg, respectively, corresponding to 2040 g DM1/m2 in both species, which is approximately equivalent to the clinical dose of trastuzumab emtansine in patients.
Štakori i majmuni dobro su podnosili trastuzumab emtanzin u dozama od najviše 20 mg/kg odnosno 10 mg/kg, koje kod obje vrste odgovaraju dozi od 2040 µg DM1/m2, što je približno jednako kliničkoj dozi trastuzumab emtanzina koja se primjenjuje u bolesnika.
Administration of Truvada every 48 hours is recommended based on modelling of single-dose pharmacokinetic data for emtricitabine and tenofovir disoproxil fumarate in non-HIV infected subjects with varying degrees of renal impairment (see section 4.4).
Primjena Truvade svakih 48 sati preporučuje se na temelju modela farmakokinetičkih podataka za pojedinačnu dozu emtricitabina i tenofovirdizoproksilfumarata u ispitanika koji nisu zaraženi virusom HIV-a, s različitim stupnjevima oštećenja funkcije bubrega (vidjeti dio 4.4).
Administration of ulipristal acetate (10 mg tablet) together with the proton pump inhibitor esomeprazole (20 mg daily for 6 days) resulted in approximately 65% lower mean Cmax, a delayed Tmax (from a median of 0.75 hours to 1.0 hours) and 13% higher mean AUC.
Primjena ulipristalacetata (tableta od 10 mg) zajedno s inhibitorom protonske pumpe esomeprazolom (20 mg dnevno tijekom 6 dana) rezultirala je s oko 65% nižom srednjom vrijednosti CRmaxR, kasnijim TRmaxR (od medijana 0,75 sati do 1,0 sata) i 13% višom srednjom vrijednosti AUC-a.
Administration of ulipristal acetate together with a high-fat breakfast resulted in approximately 45% lower mean Cmax, a delayed Tmax (from a median of 0.75 hours to 3 hours) and 25% higher mean AUC0-∞ compared with administration in the fasted state.
Primjena ulipristalacetata uz doručak bogat mastima rezultirala je s oko 45% smanjenjem srednje vrijednosti CRmaxR, odgođenim TRmaxR (sa medijana od 0,75 sati na 3 sata) i 25% višom srednjom vrijednosti AUCR0-∞R u usporedbi s primjenom natašte.
Administration of umeclidinium bromide may produce paradoxical bronchospasm that may be life- threatening.
Primjena umeklidinijeva bromida može uzrokovati paradoksalni bronhospazam, koji može biti opasan po život.
Administration of unconjugated pneumococcal polysaccharides at 13 months following the primary series with Prevenar elicited an anamnestic antibody response for the 7 serotypes included in the vaccine, indicating that priming had occurred.
Primjena nekonjugiranih pneumokoknih polisaharida u 13. mjesecu nakon primjene primarne serije Prevenara izazvala je anamnestički odgovor protutijela na 7 serotipova uključenih u cjepivo, što pokazuje da je došlo do primarne reakcije (engl. priming).
administration of Victrelis
Victrelis i takrolimusa iziskuje
Administration of Vimizim should be carried out by an appropriately trained healthcare professional with the ability to manage medical emergencies.
Vimizim mora davati zdravstveni djelatnik odgovarajuće educiran za zbrinjavanje hitnih stanja.
Administration of Viread 33 mg/g granules to provide a reduced daily dose of tenofovir disoproxil fumarate is recommended for adult patients with creatinine clearance < 50 ml/min, including haemodialysis patients.
Primjena Viread 33 mg/g granula za omogućavanje snižene dnevne doze tenofovirdizoproksilfumarata preporučuje se za odrasle pacijente s klirensom kreatinina < 50 ml/min, uključujući pacijente na hemodijalizi.
Administration of VIZAMYL and conduct of the procedure
Primjena VIZAMYL-a i provedba postupka
Administration of VWF allows correction of the haemostatic abnormalities exhibited by patients who suffer from VWF deficiency (VWD) at two levels:
Primjena VWF omogućava korekcije poremećaja hemostaze u bolesnika koji pate od manjka VWF (von Willebrandova bolest) na dvije razine:
Administration of VWF allows correction of the haemostatic abnormalities exhibited by patients who suffer from VWF deficiency (VWD) at two levels:
Primjenu VWF omogućava korekcija poremećaja hemostaze u bolesnika koji pate od manjka VWF (von Willebrandova bolest) na dvije razine:
Administration of Xofigo and conduct of the procedure
Primjena lijeka Xofigo i provođenje postupka
Administration of ZALTRAP/FOLFIRI should be delayed until neutrophil count is 1.5 x 109/L (see section 4.2).
Primjenu protokola ZALTRAP/FOLFIRI treba odgoditi dok broj neutrofila ne bude 1,5 x 109/l (vidjeti dio 4.2).
Administration of ZALTRAP/FOLFIRI should be delayed until neutrophil count is 1.5 x 109/L or platelet count is
Primjenu protokola ZALTRAP/FOLFIRI treba odgoditi dok broj neutrofila ne bude 1,5 x 109/l ili broj trombocita
Administration process
Postupak primjene
Administration should be performed as follows: Haemodialysis patients:
Primjenjuje se na sljedeći način: Bolesnici na hemodijalizi:
Administration should commence within 5 days after the completion of surgery as soon as the patient's clinical condition is stabilised.
S primjenom treba započeti u roku od 5 dana nakon završetka operacije, čim se kliničko stanje bolesnika stabilizira.
administration site
mjestu primjene
ADMINISTRATION SITE
NA MJESTU PRIMJENE
administration site conditions
mjestu primjene
administration site conditions
Opći poremećaji i reakcije na mjestu primjene
Administration Site Conditions
poremećaji i reakcije na mjestu primjene
ADMINISTRATION SYSTEM LABEL
NALJEPNICA SUSTAVA ZA PRIMJENU
Administration to both eyes concurrently is not recommended (see section 4.4).
Primjena u oba oka istovremeno nije preporučljiva (vidjeti dio 4.4).
Administration to both eyes concurrently is not recommended (see SmPC section 4.4).
Primjena u oba oka istovremeno nije preporučljiva (vidjeti dio 4.4 sažetka opisa svojstava lijeka).
Administration via Continuous Subcutaneous Insulin Infusion (CSII)
Primjena kontinuiranom supkutanom inzulinskom infuzijom (KSII)
administration with
istodobna primjena s
administration with
produljene istodobne primjene s
administration with
telaprevir)
Administration with a high-fat meal decreased dapagliflozin Cmax by up to 50% and prolonged Tmax by approximately 1 hour, but did not alter AUC as compared with the fasted state.
Primjena lijeka uz punomastan obrok smanjila je vrijednost Cmax dapagliflozina do 50% i produljila Tmax za približno 1 sat, ali nije utjecala na AUC u usporedbi s vrijednošću natašte.
Administration with a syringe
Primjena pomoću štrcaljke
Administration with an insulin delivery system
Primjena pomagalima za davanje inzulina
Administration with an insulin delivery system
Primjena pomagalima za primjenu inzulina
Administration with an insulin delivery system
Primjena s pomagalima za primjenu inzulina
administration with dasabuvir and
istodobna primjena s
administration with ddI+d4T
vrijeme s ddI+d4T (natašte)
Administration with FlexPen
Primjena s FlexPen brizgalicom
Administration with FlexTouch
Primjena FlexTouch brizgalicom
Administration with FlexTouch
Primjena s FlexTouch brizgalicom
administration with food
primjena s hranom snizila
Administration with food
Primjena uz hranu
Administration with food may increase exposure to Lojuxta.
Primjena s hranom može povećati izloženost lijeku Lojuxta.
Administration with InnoLet
Primjena s InnoLet brizgalicom
Administration with light meals (e.g., dry toast with jam or fruit conserve, apple juice, and coffee with skimmed or fat–free milk and sugar or corn flakes, skimmed or fat–free milk and sugar) resulted in plasma concentrations comparable to the corresponding fasted values.
Primjena uz lagane obroke (npr. prepečenac s marmeladom ili džemom od voća, jabučni sok i kava s obranim ili nemasnim mlijekom i šećerom ili kukuruzne pahuljice s obranim ili nemasnim mlijekom i šećerom) dovela je do koncentracija u plazmi koje su bile slične vrijednostima natašte.
Administration without food could be associated with a net loss of efficacy due to sub-optimal exposure.
Primjena bez hrane mogla bi rezultirati neto gubitkom djelotvornosti zbog suboptimalne izloženosti.
Administration-related reactions
Reakcije povezane s primjenom lijeka
Administration-related reactions (systemic non allergic)**
reakcije povezane s primjenom lijeka (sistemske nealergijske)
administration.
telaprevira.
Administration:
Način upotrebe:
Administration:
Primjena:
Administration: when reconstitution and dilution are performed under aseptic conditions ORENCIA infusion solution can be used immediately or within 24 hours if stored refrigerated at 2°C to 8°C. However, for microbiological reasons, it is to be used immediately.
Primjena: kada su priprema i razrjeđivanje provedeni u aseptičkim uvjetima, otopina za infuziju lijeka ORENCIA može se upotrijebiti odmah ili u roku od 24 sata ako se čuva u hladnjaku na temperaturi od 2°C do 8°C. Međutim, zbog mikrobioloških razloga, mora se upotrijebiti odmah.
Administrator’s Instructions
Upute za osobu koja primjenjuje lijek
adnormal x-rays of the lungs (lung infiltration) plum-coloured, raised, painful sores on the limbs and sometimes the face and neck with fever (Sweets syndrome)
abnormalni rendgenski nalaz pluća (infiltracija pluća) odignute, bolne promjene tamnoljubičaste boje na udovima i ponekad licu i vratu, s vrućicom (Sweetsov sindrom)
Adolescent
Adolescenti
Adolescent Schizophrenia Study: R076477-PSZ-3003: 26-week, flexible-dose, active-controlled Intent-to-Treat Analysis Set.
Ispitivanje shizofrenije u adolescenata: R076477-PSZ-3003: Analiza podataka bolesnika s namjerom liječenja u 26-o tjednom aktivno kontroliranom ispitivanju s flekisbilnom dozom.
Adolescents (12<18 years)
Adolescenti (12 – <18 godina)
Adolescents (9 to 17 years of age)
Adolescenti (9 do 17 godina)
Adolescents (9-<18 years)
Adolescenti (9-<18 godina)
Adolescents (ages 13 to 17 years):
Adolescenti (u dobi od 13 do 17 godina):
Adolescents (ages 13 to 17 years): The pharmacokinetics of olanzapine are similar between adolescents and adults.
Adolescenti (u dobi od 13 do 17 godina):Farmakokinetika olanzapina je slična između adolescenata i odraslih.
Adolescents (from 11 years of age) and adults
Adolescenti (od 11 godina nadalje) i odrasli
Adolescents (from 11 years of age) and adults
Adolescenti (u dobi od 11 godina) i odrasli
Adolescents (from 11 years of age) and adults should receive two injections.
Adolescenti (od 11 godina nadalje) i odrasli moraju primiti dvije injekcije.
Adolescents (from 11 years of age) and adults*
Adolescenti (od 11 godina) i odrasli
Adolescents 12 years of age and older, who weigh at least 35 kg: one tablet each day with food
Adolescenti u dobi od 12 godina i stariji, koji imaju tjelesnu težinu najmanje 35 kg: jedna tableta svaki dan, s hranom
Adolescents 12 years of age and older, who weigh at least 35 kg: one tablet each day with or without food
Adolescenti u dobi od 12 godina i stariji, koji imaju tjelesnu teţinu najmanje 35 kg: jedna tableta svaki dan, s hranom ili bez nje.
adolescents 12 years of age or older adults
adolescente u dobi od 12 i više godina odrasle osobe
Adolescents aged 12 and above
Adolescenti u dobi od 12 ili više godina
adolescents aged 12 to 17 years who have enthesitis-related arthritis and have not responded adequately to or cannot take standard treatment.
adolescenata u dobi od 12 do 17 godina koji imaju artritis povezan s entezitisom te nisu primjereno odgovorili na standardno liječenje ili ga ne mogu primati.
Adolescents aged 12 to 17 years.
Adolescenti u dobi od 12 do 17 godina.
adolescents aged 12 to less than 18 years who have already been treated with other HIV medicines which are no longer fully effective due to development of resistance, or have caused side effects.
adolescenata u dobi od 12 do manje od 18 godina koji su već bili liječeni drugim lijekovima protiv HIV-a koji više nisu potpuno djelotvorni zbog razvoja rezistencije ili su prouzročili nuspojave.
adolescents aged 12 to less than 18 years.
adolescenata u dobi od 12 do manje od 18 godina.
Adolescents aged 13 years and older experienced side effects that were similar in frequency and type to those in adults except that sleepiness, uncontrollable twitching or jerking movements, restlessness, and tiredness were very common (may affect more than 1 in 10 patients) and upper abdominal pain, dry mouth, increased heart rate, weight gain, increased appetite, muscle twitching, uncontrolled movements of the limbs, and feeling dizzy, especially when getting up from a lying or sitting position, were common (may affect up to 1 in 10 patients).
Adolescenti u dobi od 13 ili više godina imali su nuspojave slične učestalosti i vrste kao i odrasli bolesnici, osim što su pospanost, nekontrolirano trzanje mišića ili trzajni pokreti, nemir i umor bili vrlo česti (javljali su se u više od 1 na 10 bolesnika), dok su bol u gornjem dijelu trbuha, suha usta, ubrzani otkucaji srca, povećanje tjelesne težine, pojačan apetit, trzanje mišića, nekontrolirani pokreti udova i osjećaj omaglice, osobito pri ustajanju iz ležećeg ili sjedećeg položaja, bili česti (javljali su se u više od 1 na 10 bolesnika).
Adolescents and adults from 13 years of age
Adolescenti i odrasli od navršenih 13 godina
Adolescents and children aged 2 years and older patients
Adolescenti i djeca u dobi od 2 ili više godina
adolescents)
(djeca i adolescenti)
adolescents))
(djeca i adolescenti)
Adolescents, children and infants over the age of 3 months: the recommended oral dosage is
Adolescenti, djeca i dojenčad starija od 3 mjeseca: preporučeno oralno doziranje:
Adolescents, children and infants: adverse reactions and serious laboratory abnormalities reported to occur in paediatric patients ranging in age from birth through adolescence who received stavudine in clinical studies were generally similar in type and frequency to those seen in adults.
Adolescenti, djeca i dojenčad: opisane su nuspojave i ozbiljna odstupanje abnormalnosti laboratorijskih vrijednosti u pedijatrijskih bolesnika u rasponu godina od rođenja do adolescencije, koji su primali stavudin u kliničkim ispitivanjima, u sličnom opsegu vrste i učestalosti kao i u odraslih bolesnika.
Adolescents, children and infants: the recommended oral dosage is
Adolescenti, djeca i dojenčad starija od 3 mjeseca: preporučeno oralno doziranje:
Adolescents: ellaOne is suitable for any woman of child bearing age, including adolescents.
Adolescenti: ellaOne je pogodna za sve žene reproduktivne dobi, uključujući adolescentice.
Adolescents: the safety profile observed in women less than 18 years old in studies and post-marketing is similar to the safety profile in adults during the phase III program (Section 4.2).
Adolescenti: sigurnosni profil opažen u žena mlađih od 18 godina tijekom ispitivanja i nakon stavljanja lijeka u promet, sličan je sigurnosnom profilu u odraslih žena tijekom ispitivanja faze III (vidjeti dio 4.2).
ADR
Nuspojava
ADRa
Nuspojavaa
ADRa,b
Nuspojavaa,b
Adrenal
Nadbubrežna žlijezda
Adrenal
Nadbubrežne žlijezde
Adrenal crisis as a cause of the patient’s symptoms must be excluded.
Mora se isključiti adrenalna kriza kao uzrok simptoma bolesnika.
Adrenal function
Funkcija nadbubrežnih žlijezda
Adrenal function should be monitored at regular intervals since adrenal insuficiency can occur during the treatment under conditions of a relative cortisol deficiency due to an increased glucocorticoid demand (e.g. in case of stress, surgery, or infection); and/or in case of Ketoconazole HRA overtreatment (for the patients treated with a block-only regimen); or if there is insufficient glucocorticoid replacement therapy (for the patients treated with a block-and-replace regimen).
Adrenalnu funkciju treba redovito pratiti budući da tijekom liječenja može doći do adrenalne insuficijencije u uvjetima relativne deficijencije kortizola zbog povećane potrebe za glukokortikoidima (npr. u slučaju stresa, operacije ili infekcije); i/ili u slučaju prekomjerne terapije Ketoconazoleom HRA (u bolesnika liječenih režimom liječenja samo blokadom); ili ako je nadomjesno liječenje glukokortikoidima nedovoljno (u bolesnika liječenih režimom liječenja blokadom i nadomještanjem).
Adrenal function”.
Funkcija nadbubrežnih žlijezda“.
Adrenal gland problems (related to salt and water problems), muscle weakness and/or muscle pain.
Tegobe s nadbubrežnim žlijezdama (povezane s problemima s razinom soli i vode), slabost u mišićima i/ili bolovi u mišićima.
adrenal glands not working properly – this may cause weakness, tiredness, loss of appetite, skin discolouration
neispravan rad nadbubrežnih žlijezdi – to može uzrokovati slabost, umor, gubitak apetita, promjenu boje kože
adrenal glands not working properly – this may cause weakness, tiredness, loss of appetite, skin discolouration
neispravan rad nadbubrežnih žlijezdi – to može uzrokovati slabost, umor, gubitak apetita, promjenu boje kože,
Adrenal glands not working properly, inflammation of the thyroid gland
nepravilan rad nadbubrežnih žlijezda, upala štitnjače
Adrenal haemorrhage
krvarenje u nadbubrežnoj žlijezdi
adrenal insufficiency
insuficijencija nadbubrežne žlijezde
Adrenal insufficiency may occur and can be a serious side effect.
Može doći do ozbiljne nuspojave zatajivanja nadbubrežne žlijezde.
Adrenal insufficiency may occur in patients on ketoconazole without corticosteroid substitution (block-only regimen) or if there is an insufficient glucocorticoid replacement therapy (for the patients treated with a block- and-replace regimen).
Može doći do adrenalne insuficijencije u bolesnika liječenih ketokonazolom bez nadomjesne terapije kortikosteroidima (režim liječenja samo blokadom) ili u slučaju nedostatne nadomjesne terapije glukokortikoidima (u bolesnika liječenih režimom blokade i nadomještanja).
Adrenal insufficiency*
Adrenalna insuficijencija
adrenal insufficiency, hypopituitarism, hypophysitis, hyperthyroidism, thyroiditis, hyperglycaemiab
insuficijencija nadbubrežne žlijezde, hipopituitarizam, hipofizitis, hipertireoza, tireoiditis, hiperglikemijab
adrenal insufficiency, hypopituitarism, hypophysitis, thyroiditis, diabetic ketoacidosis
insuficijencija nadbubrežne žlijezde, hipopituitarizam, hipofizitis, tireoiditis, dijabetička ketoacidoza
adrenal insufficiency, hypothyroidism
insuficijencija nadbubrežnih žlijezda, hipotireoidizam
adrenal insufficiency, thyroiditis
insuficijencija nadbubrežne žlijezde, tireoiditis
Adrenal insufficiency: fatigue, abdominal pain, nausea, vomiting, diarrhoea, confusion
Zatajenje nadbubrežne žlijezde: umor, bol u trbuhu, mučnina, povraćanje, proljev, smetenost
adrenal insufficiencyc, secondary adrenocortical insufficiencyd, hyperthyroidismc, hypogonadism
insuficijencija nadbubrežne žlijezdec,sekundarna adrenokortikalna insuficijencijad, hipertireoidizamc, hipogonadizam
Adrenal insuficiency (diminution of the amount of hormones (cortisol)
zatajivanje nadbubrežne žlijezde (smanjenje količine hormona (kortizol))
adrenaline and isoprenaline (both used for heart attacks) anticoagulants of the warfarin type (that prevent blood clotting).
adrenalin i izoprenalin (oboje se koriste za srčane udare), antikoagulansi varfarinskog tipa (koji sprječavaju zgrušavanje krvi).
adrenaline and isoprenaline (both used for heart attacks), anticoagulants of the warfarin type (that prevent blood clotting).
adrenalin i izoprenalin (oboje se koriste za srčane udare), antikoagulansi varfarinskog tipa (koji sprječavaju zgrušavanje krvi).
adrenaline and sympathicomimetics (to increase heart beat, to treat asthma or nasal congestion, coughs and colds or used in life-threatening emergencies)
adrenalin i simpatomimetici (za povećanje brzine rada srca, za liječenje astme ili začepljenosti nosa, kašlja i prehlade ili za primjenu u hitnim, životno opasnim stanjima)
adrenaline, used for severe allergic reactions
adrenalin, koji se koristi za teške alergijske reakcije,
Adrenals
0,2130
adrenals
đenče
Adrenals3
Nadbubrežne žlijezde3
Adrenergic agonists/antagonists (such as certain types of medicines used to control blood pressure by constricting blood vessels, nasal decongestants, blood pressure lowering medicines), opiate agonists/antagonists (such as medicinal products used in the treatment of drug addiction), prostaglandin inhibitors (such as nonsteroidal anti-inflammatory medicines), antidepressant medication, tryptophan and alcohol.
adrenergički agonisti/antagonisti (poput određenih vrsta lijekova koji kontroliraju krvni tlak sužavanjem krvnih žila, nazalnih dekongestata, lijekova za snižavanje krvnog tlaka), opijatski agonisti/antagonist (poput lijekova koji se primjenjuju u liječenju ovisnosti o drogama), inhibitora prostaglandina (poput nesteroidnih protuupalnih lijekova), antidepresiva, triptofana i alkohola.
ADROVANCE 70 mg/2,800 IU tablets ADROVANCE 70 mg/5,600 IU tablets Alendronic acid /colecalciferol
ADROVANCE 70 mg/2800 IU tablete ADROVANCE 70 mg/5600 IU tablete alendronatna kiselina/kolekalciferol
ADROVANCE 70 mg/2,800 IU tablets are available as modified capsule-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘710’ on the other.
ADROVANCE 70 mg/2800 IU tablete su bijele do gotovo bijele tablete oblika preinačene kapsule s oznakom kosti na jednoj strani i utisnutom oznakom '710' na drugoj.
ADROVANCE 70 mg/5,600 IU tablets are available as modified rectangle-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘270’ on the other.
ADROVANCE 70 mg/5600 IU tablete su bijele do gotovo bijele tablete oblika preinačenog pravokutnika s oznakom kosti na jednoj strani i utisnutom oznakom '270' na drugoj.
ADROVANCE 70 mg/5,600 IU tablets EU/1/06/364/006 – 2 tablets EU/1/06/364/007 – 4 tablets EU/1/06/364/008 – 12 tablets
ADROVANCE 70 mg/5600 IU tablete EU/1/06/364/006 – 2 tablete EU/1/06/364/007 – 4 tablete EU/1/06/364/008 – 12 tableta
ADROVANCE should not be given to children and adolescents less than 18 years of age.
ADROVANCE se ne smije davati djeci i adolescentima mlađima od 18 godina.
ADROVANCE should not be taken at bedtime or before arising for the day.
ADROVANCE se ne smije uzimati navečer prije spavanja niti ujutro prije ustajanja.
ADROVANCE should only be swallowed after getting up for the day with a full glass of water (not less than 200 ml).
ADROVANCE se mora progutati ujutro, nakon ustajanja, s punom čašom vode (najmanje 200 ml).